Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Patrick Burnett Sells 684 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) insider Patrick Burnett sold 684 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $16,149.24. Following the sale, the insider owned 120,466 shares in the company, valued at $2,844,202.26. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Patrick Burnett also recently made the following trade(s):

• On Monday, March 2nd, Patrick Burnett sold 6,287 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.18, for a total value of $158,306.66.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ ARQT opened at $24.17 on Thursday. The firm has a market cap of $3.02 billion, a PE ratio of -172.63 and a beta of 1.58. The firm has a fifty day moving average of $23.78 and a 200 day moving average of $25.78. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.99 and a current ratio of 3.17. Arcutis Biotherapeutics, Inc. has a one year low of $12.42 and a one year high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). The company had revenue of $105.40 million during the quarter, compared to analysts’ expectations of $103.68 million. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%. As a group, research analysts predict that Arcutis Biotherapeutics, Inc. will post 0.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ARQT shares. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday. Mizuho reduced their target price on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. TD Cowen increased their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Finally, HC Wainwright increased their target price on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.00.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong commercial performance and clinical progress: Q1 net product revenue for ZORYVE was $105.4M (up 65% YoY), the company reported positive operating cash flow, submitted an sNDA to expand ZORYVE to infants 3–24 months, completed enrollment in a pediatric MUSE trial, initiated Phase 1a/1b for ARQ‑234, and expanded the salesforce and primary care/pediatrics buildout. These developments support continued top-line growth and pipeline optionality. Read More.
• Positive Sentiment: Analyst stance remains constructive: Brokerages maintain a consensus “Moderate Buy” and a mid‑$30s consensus target, which can buoy investor sentiment as commercial momentum continues. Read More.
• Neutral Sentiment: Mixed Q1 financials: Revenue beat estimates ($105.4M vs. ~$103.7M) but GAAP EPS missed materially (loss of $0.09 vs. expected loss of $0.02). The top-line strength supports commercialization, but the EPS miss highlights continued margin/expense pressure as the company invests in growth. Read More.
• Negative Sentiment: Insider selling: Multiple insiders (including director and executives) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vested awards. While filings state routine/tax reasons, clustered sales can raise short‑term concerns about insider exposure and add selling pressure. Read More.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARQT. Suvretta Capital Management LLC lifted its stake in shares of Arcutis Biotherapeutics by 14.2% in the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock worth $347,435,000 after buying an additional 1,486,000 shares in the last quarter. Jennison Associates LLC boosted its stake in Arcutis Biotherapeutics by 10.3% during the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock worth $230,990,000 after buying an additional 1,144,714 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Arcutis Biotherapeutics by 1,228.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock worth $33,872,000 after buying an additional 1,078,546 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Arcutis Biotherapeutics during the fourth quarter worth $26,136,000. Finally, State Street Corp boosted its stake in Arcutis Biotherapeutics by 18.2% during the fourth quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after buying an additional 846,986 shares during the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.